Ivax Zyprexa Patent Challenge Could Benefit From Paxil Invalidity Ruling

 
• By The Pink Sheet

Ivax believes its challenge to Lilly's Zyprexa patent will get a boost from a recent appellate court decision invalidating a GlaxoSmithKline patent claim for Paxil

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet